SBSB
ALT icon

Sullivan, Bruyette, Speros & Blaney’s Altimmune ALT Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-421
Closed -$29K – 168
2017
Q3 		$29K Hold
421
– – ﹤0.01% 161
2017
Q2 		$40K Hold
421
– – ﹤0.01% 148
2017
Q1 		$103K Buy
421
+75
+22% +$40.1K 0.01% 145
2016
Q4 		$337K Hold
346
– – 0.03% 103
2016
Q3 		$301K Buy
346
+304
+724% +$238K 0.03% 110
2016
Q2 		$31K Buy
+42
New +$28.7K ﹤0.01% 138

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's ALT Position: Q4 2017 in Review

Sullivan, Bruyette, Speros & Blaney sold out of Altimmune (ALT) in Q4 2017, closing a stake of 421 shares — an estimated $29K sold.

Sullivan, Bruyette, Speros & Blaney first reported a position in ALT in Q2 2016 and held it in 6 quarters. The position peaked at $337K in Q4 2016. 30 funds tracked by Wall St. Rank hold ALT as of Q4 2017.

  • Sullivan, Bruyette, Speros & Blaney reported no remaining Altimmune position as of Q4 2017 after selling out during the quarter.
  • Sullivan, Bruyette, Speros & Blaney sold 421 Altimmune shares in Q4 2017, an estimated $29K.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Altimmune in Q2 2016 and held it in 6 quarters.
  • Sullivan, Bruyette, Speros & Blaney's Altimmune position peaked at $337K in Q4 2016.
  • 30 funds tracked by Wall St. Rank held Altimmune as of Q4 2017.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q4 2017, filed 13 Feb 2018.